Inhibikase Therapeutics Insider Trades
NASDAQ: IKTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 0 · $0
- Sales
- 0 · $0
- Shares bought / sold
- 0 / 0
- Net activity
- Net buying $0
Inhibikase Therapeutics insider activity
Over the last 12 months, Inhibikase Therapeutics insiders reported 5 transactions on SEC Form 4: 0 open-market purchases and 0 sales. The most recent filing shows BERMAN DENNIS N (Director) reporting a transaction in 21,854 shares at $1.26 on Jul 30, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put IKT's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
IKT insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jul 30, 2026 | BERMAN DENNIS NDirector | Option exercise | 21,854 | $27.54K | Form 4 |
| Jul 29, 2026 | RA CAPITAL MANAGEMENT, L.P. & RA Capital Healthcare Fund LP & Kolchinsky Peter & Shah Rajeev M.10% Owner | other | 18,030,000 | — | Form 4 |
| Feb 21, 2026 | Cabell ChristopherPresident & Head of R&D | Disposition | 338,282 | — | Form 4 |
| Feb 21, 2026 | Aurentz VincentDirector | Disposition | 255,299 | — | Form 4 |
| Feb 21, 2026 | Munshi AmitDirector | Disposition | 19,089 | — | Form 4 |
| Nov 21, 2025 | Sands Capital Life Sciences Pulse Fund II, L.P. & Sands Capital Alternatives, LLC & SANDS FRANK M.10% Owner | Buy | 2,068,965 | $3.00M | Form 4 |
| Feb 21, 2025 | Munshi AmitDirector | Award | 57,265 | — | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4